What did @lizdamyl actually say?
Honestly, not much of substance. The transcript is mostly fragmented filler. She mentions something called the "Cien to Cien Calibra" and says she will "put it on a little bit," which appears to reference applying or starting a GLP-1 injection. The real content of this post is the caption, not the spoken word.
The caption is a paid promotion for Fridays, a telehealth platform that prescribes GLP-1 medications, and she offers a $100 discount code for a first month. The hashtags "inyeccion" and "bajardepeso" (injection and weight loss) make the topic clear even when the verbal content does not. This is primarily an affiliate advertisement, and evaluating it as a health information video is generous, but with 241,800 views, the reach demands scrutiny regardless.
Does the science back up GLP-1 injections for weight loss?
Yes, broadly. GLP-1 receptor agonists have some of the strongest weight-loss trial data we have seen in pharmacology. But the specifics matter enormously, and no specific drug, dose, or outcome was named here.
Semaglutide (Wegovy) produced mean weight loss of around 14.9% of body weight over 68 weeks in the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine). Tirzepatide (Zepbound) outperformed that in the SURMOUNT-1 trial, with up to 20.9% body weight reduction at the highest dose (Jastreboff et al., 2022, New England Journal of Medicine). These are real, peer-reviewed results from large randomized controlled trials. So the general premise that GLP-1 injections produce meaningful weight loss is well-supported. What is not supported is the assumption that a compounded version from a telehealth provider produces the same results as a brand-name FDA-approved drug, and that distinction is never made in this video.
What did @lizdamyl get wrong, or right?
She did not say anything clinically wrong because she barely said anything clinical at all. That is both a defense and a problem.
What she got right: GLP-1 injections are a legitimate, evidence-backed tool for weight management. Telehealth platforms that prescribe them are legal and regulated in most U.S. states. Promoting access to weight loss treatment is not inherently irresponsible.
What she got wrong by omission: there is no mention of side effects, which for GLP-1 agonists include nausea, vomiting, pancreatitis risk, and potential thyroid concerns flagged in FDA labeling. There is no mention that compounded semaglutide, which many telehealth platforms dispense, is not FDA-approved and lacks the bioequivalence data of Wegovy or Ozempic. The FDA issued warnings about compounded semaglutide as recently as 2024. A $100 discount code as the primary call to action in a health-adjacent video to nearly a quarter million viewers is not neutral content marketing.
What should you actually know before clicking that link?
If you are considering a GLP-1 through a telehealth platform, the drug source and provider credentials matter more than a discount code.
- Ask explicitly whether the medication is FDA-approved (Wegovy, Zepbound, Ozempic) or compounded. Compounded semaglutide has been the subject of FDA advisories warning about dosing errors and quality inconsistencies.
- GLP-1 medications are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, per FDA prescribing information.
- Common side effects reported in STEP 1 (Wilding et al., 2021) included nausea in 44% of participants and vomiting in 24%. These are not rare edge cases.
- Telehealth prescribing is legitimate when a licensed clinician reviews your full medical history. A checkout discount code does not substitute for that review.
- Weight loss results in trials reflect specific doses over specific durations. Individual results vary substantially. No social media post can predict your outcome.
Is this video harmful or just incomplete?
Incomplete is the honest answer, with some concern about scale. At 241,800 views, even a vague promotional video shapes how people think about these medications.
The creator is not making false medical claims here, but the framing of a GLP-1 injection as a straightforward consumer purchase, with a promo code to sweeten the deal, skips over the clinical gatekeeping that makes these drugs reasonably safe. Research from Suran (2023, JAMA) noted that social media GLP-1 promotion frequently omits contraindications and long-term unknowns. That pattern applies here. The video is not dangerous misinformation. It is the kind of comfortable omission that adds up across a platform.